News
ARGX
950.95
-0.95%
-9.09
argenx Is Maintained at Overweight by Piper Sandler
Dow Jones · 10h ago
Piper Sandler Maintains Overweight on argenx, Raises Price Target to $1350
Benzinga · 10h ago
Weekly Report: what happened at ARGX last week (1109-1113)?
Weekly Report · 14h ago
Argenx Earnings Call Highlights Growth and 2027 Launches
TipRanks · 1d ago
argenx Price Target Cut to $1130.00/Share From $1190.00 by Morgan Stanley
Dow Jones · 3d ago
argenx Is Maintained at Overweight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Overweight on argenx, Lowers Price Target to $1130
Benzinga · 3d ago
Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals
NASDAQ · 3d ago
Roth Capital biotech analysts hold analyst/industry conference call
TipRanks · 5d ago
argenx: Unnatural Products Deal Changes Risk Profile
Seeking Alpha · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Myomo (MYO), Maze Therapeutics, Inc. (MAZE)
TipRanks · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Claritev (CTEV), Aldeyra Therapeutics (ALDX) and Argenx Se (ARGX)
TipRanks · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Voyager Therapeutics (VYGR)
TipRanks · 6d ago
If You Invested $100 In argenx Stock 5 Years Ago, You Would Have This Much Today
Benzinga · 11/09 20:00
argenx SE Reports Phase 3 ALKIVIA Trial of Efgartigimod Met Primary Endpoint in Autoimmune Myositis
NASDAQ · 11/09 18:11
iShares Biotechnology ETF Experiences Big Outflow
NASDAQ · 11/09 15:49
argenx SE Announces Agreement to Acquire Unnatural Products, Inc. for Up to Approximately $1.15 billion
NASDAQ · 11/09 13:12
arGEN X (0QW0) Gets a Buy from J.P. Morgan
TipRanks · 11/09 10:55
Argenx to acquire Unnatural Products for $1.15B
TipRanks · 11/09 10:30
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade
The Motley Fool · 11/09 10:04
More
Webull provides a variety of real-time ARGX stock news. You can receive the latest news about Argenx Se through multiple platforms. This information may help you make smarter investment decisions.
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.